HCM News and Press, HUTCHMED (China) Limited From 03/04/22

Gainers: Atreca (NASDAQ:BCEL) +20%. Alignment Healthcare (NASDAQ:ALHC) +16%. Puma Biotechnology (NASDAQ:PBYI) +15%. Humanigen (NASDAQ:HGEN) +13%. agilon health (NYSE:AGL) +8%. Losers: DBV Technologies (NASDAQ:DBVT) -22%. Ocugen (NASDAQ:OCGN) -20%.  ...

HUTCHMED (China) Limited (HCM) Q4 2021 Earnings Conference Call March 03, 2022, 08:00 AM ET Company Participants Christian Hogg - Chief Executive Officer Hong Chen - Senior Vice President and Chief Commercial Officer, China Weiguo Su - Executive Director and Chief Scientific Officer Marek Kan...

Hutchmed (NASDAQ:HCM) has announced the retirement of its CEO Christian Hogg. Hogg has been with the company for almost 22 years, including 15 years as Executive Director and CEO. Weiguo Su, who has been with the firm for about 17 years, including about 10 years as Chief Scientific Officer an...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces: (a) the retirement of Mr. Christian Hogg after almost 22 years with t...

Hutchison China MediTech press release (NASDAQ:HCM): FY GAAP EPS of -$0.25 beats by $1.54. Revenue of $356.1M (+56.2% Y/Y) beats by $17.33M. For further details see: Hutchison China MediTech GAAP EPS of -$0.25 beats by $1.54, revenue of $356.1M beats by $17.33M

Oncology/Immunology revenues up 296% to $119.6 million, due to ELUNATE ® growth and the 2021 launches of SULANDA ® and ORPATHYS ® ; Positive SAVANNAH, CALYPSO and VIKTORY studies triggered five registration studies on ORPATHYS ...

Hutchmed (China) (NASDAQ:HCM) received approval to market fruquintinib (sold as Elunate in China) to treat metastatic colorectal cancer in the Macau Special Administrative Region. The approval follows the latest update to the provisions on new drug importation which a...

HONG KONG and FLORHAM PARK, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has received approval to market fruquintinib (ELUNATE ® in China), a selective and po...

BEIJING, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products ...

U.S.-listed Chinese biotech companies are trading lower after the U.S. commerce department added life-sciences company, WuXi Biologics (OTCPK:WXXWY -13.5%) (OTCPK:WXIBF -22.6%), to its “unverified” list for exporters. Notable decliners include I-Mab (IMAB -5.7%) and BeiGene (BGN...